Hyundai Bioscience Co. Ltd (048410) — Capital Reinvestment Ratio
Latest as of December 2024:
0.96x
Hyundai Bioscience Co. Ltd (048410) has a Capital Reinvestment Ratio of 0.96x as of December 2024, meaning it reinvests 1% of its operating cash flow (₩2.26 Billion) in capital expenditures (₩2.17 Billion). See cash generation quality of Hyundai Bioscience Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.96x
Capex / Operating Cash Flow
Operating Cash Flow
₩2.26 Billion
KRW
Capital Expenditures
₩2.17 Billion
KRW
Data as of
Dec 2024
Most recent filing
Hyundai Bioscience Co. Ltd Capital Reinvestment Ratio (2008–2024)
This chart tracks Hyundai Bioscience Co. Ltd's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Hyundai Bioscience Co. Ltd (2008–2024)
Year-by-year Capital Reinvestment Ratio for Hyundai Bioscience Co. Ltd from 2008 to 2024. For live market cap and broader valuation context, see Hyundai Bioscience Co. Ltd stock valuation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.96x | ₩2.26 Billion | ₩2.17 Billion | ▼ -71.4% |
| 2020 | 3.36x | ₩7.50 Billion | ₩25.20 Billion | ▲ +906.0% |
| 2019 | 0.33x | ₩9.18 Billion | ₩3.07 Billion | ▼ -76.3% |
| 2018 | 1.41x | ₩5.01 Billion | ₩7.07 Billion | ▼ -81.0% |
| 2015 | 7.41x | ₩87.36 Million | ₩647.57 Million | ▲ +980.0% |
| 2014 | 0.69x | ₩1.22 Billion | ₩840.18 Million | ▲ +917.4% |
| 2011 | 0.07x | ₩3.97 Billion | ₩267.78 Million | ▼ -82.1% |
| 2008 | 0.38x | ₩10.37 Billion | ₩3.92 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow